Next 10 |
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for ...
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well a...
2024-05-17 22:15:24 ET Dyadic International, Inc. (DYAI) Q1 2024 Earnings Conference Call May 14, 2024 05:00 PM ET Company Participants Mark Emalfarb - President & CEO Ping Rawson - CFO Joseph Hazelton - COO Conference Call Participants John Vande...
2024-05-14 16:11:37 ET More on Dyadic International Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript Dyadic's Michael Tarnok to step down as Chairman of the board of directors Dyadic announces strategic partnership agreement to develop rabies v...
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against C...
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and ...
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins f...
2024-04-24 17:36:16 ET More on Dyadic International Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript Dyadic's Michael Tarnok to step down as Chairman of the board of directors Dyadic announces strategic partnership agreement to develop rabies v...
2024-03-28 22:22:08 ET Dyadic International, Inc. (DYAI) Q4 2023 Earnings Conference Call March 28, 2024 05:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Operating Of...
2024-03-28 16:03:21 ET More on Dyadic International Dyadic's Michael Tarnok to step down as Chairman of the board of directors Dyadic announces strategic partnership agreement to develop rabies vaccines Seeking Alpha’s Quant Rating on Dyadic International...
News, Short Squeeze, Breakout and More Instantly...
Dyadic International Inc. Company Name:
DYAI Stock Symbol:
OTCMKTS Market:
Dyadic International Inc. Website:
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for ...
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well a...
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against C...